HTML Microdata document

This HTML5 document contains 73 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n6	http://linked.opendata.cz/resource/drugbank/drug/DB01141/identifier/kegg-compound/
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n26	http://linked.opendata.cz/resource/drugbank/drug/DB01141/identifier/pubchem-compound/
n16	http://linked.opendata.cz/resource/AHFS/
n23	http://linked.opendata.cz/resource/mesh/concept/
n29	http://linked.opendata.cz/resource/drugbank/company/
foaf	http://xmlns.com/foaf/0.1/
n25	http://www.rxlist.com/cgi/generic4/
n28	http://linked.opendata.cz/resource/drugbank/drug/DB01141/identifier/pubchem-substance/
n30	http://linked.opendata.cz/resource/drugbank/drug/DB01141/identifier/kegg-drug/
n27	http://linked.opendata.cz/resource/drugbank/dosage/
n4	http://linked.opendata.cz/resource/drugbank/drug/DB01141/identifier/drugbank/
n13	http://bio2rdf.org/drugbank:
n31	http://linked.opendata.cz/resource/drugbank/drug/DB01141/identifier/national-drug-code-directory/
adms	http://www.w3.org/ns/adms#
n8	http://linked.opendata.cz/resource/drugbank/patent/
n24	http://linked.opendata.cz/resource/drugbank/drug/DB01141/identifier/chemspider/
n20	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n21	http://linked.opendata.cz/resource/drugbank/drug/DB01141/identifier/chebi/
n11	http://linked.opendata.cz/resource/drugbank/medicinal-product/
owl	http://www.w3.org/2002/07/owl#
n22	http://linked.opendata.cz/ontology/mesh/
n5	http://linked.opendata.cz/ontology/drugbank/
n10	http://www.drugs.com/cdi/
n7	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#
n18	http://linked.opendata.cz/resource/drugbank/drug/DB01141/identifier/wikipedia/
n17	http://linked.opendata.cz/resource/drugbank/drug/DB01141/identifier/pharmgkb/
n19	http://linked.opendata.cz/resource/atc/
n15	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB01141
rdf:type: n5:Drug
n5:description: Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
n5:dosage: n27:271B47F2-363D-11E5-9242-09173F13E4C5 n27:271B47F3-363D-11E5-9242-09173F13E4C5
n5:generalReferences: # Grover ND: Echinocandins: A ray of hope in antifungal drug therapy. Indian J Pharmacol. 2010 Feb;42(1):9-11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20606829 # Bormann AM, Morrison VA: Review of the pharmacology and clinical studies of micafungin. Drug Des Devel Ther. 2009 Dec 29;3:295-302. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20054447 # Vehreschild JJ, Cornely OA: Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice. Future Microbiol. 2006 Aug;1:161-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17661660 # Groll AH, Stergiopoulou T, Roilides E, Walsh TJ: Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs. 2005 Apr;14(4):489-509. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15882123 # Chandrasekar PH, Sobel JD: Micafungin: a new echinocandin. Clin Infect Dis. 2006 Apr 15;42(8):1171-8. Epub 2006 Mar 14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16575738 # Wiederhold NP, Lewis JS 2nd: The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother. 2007 Jun;8(8):1155-66. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17516879 # Ikeda F, Tanaka S, Ohki H, Matsumoto S, Maki K, Katashima M, Barrett D, Aoki Y: Role of micafungin in the antifungal armamentarium. Curr Med Chem. 2007;14(11):1263-75. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17504145 # Sucher AJ, Chahine EB, Balcer HE: Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009 Oct;43(10):1647-57. Epub 2009 Sep 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19724014 # Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm. 2006 Sep 15;63(18):1693-703. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16960253 # Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm. 2006 Oct 1;63(19):1813-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16990627
n5:group: approved investigational
n5:halfLife: 14-17 hours
n5:indication: For use in the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.
owl:sameAs: n13:DB01141 n20:DB01141
dcterms:title: Micafungin
adms:identifier: n4:DB01141 n6:C15819 n17:PA164781026 n18:Micafungin n21:600520 n24:2339421 n26:477468 n28:46508208 n30:D02465 n31:0469-3250-10
n5:mechanismOfAction: Micafungin inhibits the synthesis of beta-1,3-D-glucan, an essential component of fungal cell walls which is not present in mammalian cells. It does this by inhibiting beta-1,3-D-glucan synthase.
n5:packager: n29:271B47EF-363D-11E5-9242-09173F13E4C5
n5:patent: n8:5376634 n8:6774104 n8:2202058 n8:2044746
n5:routeOfElimination: Fecal excretion is the major route of elimination (total radioactivity at 28 days was 71% of the administered dose).
n5:synonym: Mycamine
n5:toxicity: Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.
n5:volumeOfDistribution: * 0.39 ± 0.11 L/kg [adult patients with esophageal candidiasis]
n15:hasAHFSCode: n16:8-14-16
n5:proteinBinding: Highly (>99%) protein bound in vitro, independent of plasma concentrations over the range of 10 to 100 µg/mL. The primary binding protein is albumin; however, micafungin, at therapeutically relevant concentrations, does not competitively displace bilirubin binding to albumin. Micafungin also binds to a lesser extent to a1-acid-glycoprotein.
n22:hasConcept: n23:M0414899
foaf:page: n10:micafungin.html n25:mycamine.htm
n5:IUPAC-Name: n7:271B47F8-363D-11E5-9242-09173F13E4C5
n5:InChI: n7:271B47FE-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula: n7:271B47FD-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight: n7:271B47FA-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight: n7:271B47FB-363D-11E5-9242-09173F13E4C5
n5:SMILES: n7:271B47FC-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility: n7:271B47F6-363D-11E5-9242-09173F13E4C5 n7:271B480E-363D-11E5-9242-09173F13E4C5
n5:logP: n7:271B47F4-363D-11E5-9242-09173F13E4C5 n7:271B47F7-363D-11E5-9242-09173F13E4C5 n7:271B480F-363D-11E5-9242-09173F13E4C5
n5:logS: n7:271B47F5-363D-11E5-9242-09173F13E4C5
n15:hasATCCode: n19:J02AX05
n5:H-Bond-Acceptor-Count: n7:271B4804-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count: n7:271B4805-363D-11E5-9242-09173F13E4C5
n5:InChIKey: n7:271B47FF-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-: n7:271B4800-363D-11E5-9242-09173F13E4C5
n5:Polarizability: n7:271B4802-363D-11E5-9242-09173F13E4C5
n5:Refractivity: n7:271B4801-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count: n7:271B4803-363D-11E5-9242-09173F13E4C5
n5:absorption: Not absorbed orally
n5:affectedOrganism: Aspergillis, Candida and other fungi
n5:casRegistryNumber: 235114-32-6
n5:category
n5:clearance: * 0.359 +/- 0.179 mL/min/kg [Adult Patients with IC with 100 mg] * 0.321 +/- 0.098 mL/min/kg [HIV- Positive Patients with EC with 50 mg] * 0.327 +/- 0.093 mL/min/kg [HIV- Positive Patients with EC with 100 mg] * 0.340 +/- 0.092 mL/min/kg [HIV- Positive Patients with EC with 150 mg] * 0.214 +/- 0.031 mL/min/kg [hematopoietic stem cell transplant recipients 3 mg/kg] * 0.204 +/- 0.036 mL/min/kg [hematopoietic stem cell transplant recipients 4 mg/kg] * 0.224 +/- 0.064 mL/min/kg [hematopoietic stem cell transplant recipients 6 mg/kg] * 0.223 +/- 0.081 mL/min/kg [hematopoietic stem cell transplant recipients 8 mg/kg]
n5:containedIn: n11:271B47F0-363D-11E5-9242-09173F13E4C5 n11:271B47F1-363D-11E5-9242-09173F13E4C5
n5:Bioavailability: n7:271B480A-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter: n7:271B480C-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule: n7:271B480D-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings: n7:271B4809-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge: n7:271B4808-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five: n7:271B480B-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name: n7:271B47F9-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-: n7:271B4806-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-: n7:271B4807-363D-11E5-9242-09173F13E4C5